Milwaukee Team Wins NIH R01 to Develop Novel Anxiolytic Compounds Targeting the Endocannabinoid System
Nearly 1/3 of Americans will experience an anxiety disorder in their lifetime resulting in impaired social function and reduction of quality of life. Unfortunately, existing anxiety medications suffer from delayed or inadequate efficacy and sedative-hypnotic effects. Development of additional anxiolytics …